When Shaun Tierney was diagnosed with an aggressive form of kidney cancer in 2007, the prognosis was grim.
Twelve years on, the 64-year-old is still living an active life, and even participating in marathon walks for cancer research — an outcome made possible by work that was awarded this year’s Nobel prize in medicine.
Tierney’s case is a telling illustration of how seemingly esoteric scientific research makes its way from the lab to the real world — a journey that can save lives.
“It’s an exciting time,” said Tierney’s doctor, oncologist Toni Choueiri, who works at the Dana-Farber Cancer Institute in Boston and is a professor at Harvard Medical School.
“We’re not curing everyone. Definitely not. But this is crazy — this is a disease that went from a death sentence, ‘Go do your work, start having your will ready etc,’ to people living years,” Choueiri said.
Americans William Kaelin and Gregg Semenza, and Britain’s Peter Ratcliffe, were last month awarded the Nobel for their work on how human cells sense and adapt to oxygen.
They began their research in the early 1990s, and the first therapeutic applications appeared in the mid-2000s.
Tierney, a former design engineer, was embarking on a new chapter with his wife as an empty nester when he was diagnosed with stage four renal cell carcinoma.
His hopes of surviving five years at the time? Just 3 to 5 percent.
“Our legs were cut out from beneath us,” Tierney told reporters.
However, that changed when he received Sutent, one of a then-new class of drugs called angiogenesis inhibitors that stop the growth of new blood vessels that feed cancer cells.
The development of the treatment that has prolonged Tierney’s life was a direct result of the trio’s Nobel-winning research.
Kaelin, who runs a laboratory at Dana-Farber and also teaches at Harvard, first started studying oxygen sensing because he was investigating a rare, inherited condition called Von Hippel-Lindau’s (VHL) disease.
The illness causes its carriers to develop tumors, such as kidney cancers, that overproduce distress signals associated with having a lack of oxygen.
One of these signals is a protein called vascular endothelial growth factor (VEGF). It stimulates the growth of new blood vessels, thus spreading the cancer.
Kaelin uncovered the process by which the gene responsible for VHL disease regulated VEGF and made sure it was not overproduced.
This gene is responsible for some types of kidney cancer that occur even in people not born with VHL disease, because it can sometimes mutate over time in the kidney.
Sutent is now one of several approved VEGF inhibitors designed to treat these cancers.
It has not been an easy ride for Tierney: The drug has toxicities and his treatment is “very rough,” in his words.
After first blasting the site with radiation for several weeks, he began taking Sutent orally, initially on a standard course of 28 days treatment and 14 days recovery.
At first the side effects, including severe diarrhea and weight loss, proved too debilitating, leading Choueiri to experiment with different dosing schedules, settling for the past four years on five days treatment, followed by nine days rest and recovery.
Tierney is something of an outlier in that he has been exceptionally receptive to the drug, but many are not so lucky, Choueiri said.
“Most, but not all, patients benefit. Even in the group that benefits, many of them will benefit for months or a few years and then the cancer will eventually progress,” Kaelin said.
The reasons are not fully clear, but are probably linked to a tumor’s genetic makeup — one reason why Tierney has volunteered for studies to try to solve the question.
Choueiri said he often has to prescribe patients a combination of VEGF inhibitors as well as immunotherapy drugs — an even newer class of treatment that turn the body’s own natural defenses against the cancer.
According to Kaelin, researchers can go farther down the pathway of oxygen-regulating drugs.
He is working with a company called Peleton on a new treatment that acts on an earlier link in the chain of this pathway and inhibits not just VEGF, but other cancer-causing substances.
Early trials are promising, but the work continues.
For Kaelin, a physician-scientist who works both in the lab and with patients, that work is particularly rewarding.
“To now think that I along with many, many, many others who worked in the field, I have been able to move the ball forward and get a better therapy for these patients is just amazing,” he said.
Tierney counts himself lucky to have benefited from various innovations, and is determined to make the most of his time — for example regularly taking part in kidney cancer research fundraising efforts such as charity walks.
“My prolonged survival allowed me to see all of our three children marry, start families, buy houses and become real decent, great adults,” he said.
He was also able to meet his six grandchildren.
“My kind of number one goal right now, the longer I survive, is to just imprint as many memories as I can on these children,” Tierney said.
‘IN A DIFFERENT PLACE’: The envoy first visited Shanghai, where he attended a Chinese basketball playoff match, and is to meet top officials in Beijing tomorrow US Secretary of State Antony Blinken yesterday arrived in China on his second visit in a year as the US ramps up pressure on its rival over its support for Russia while also seeking to manage tensions with Beijing. The US diplomat tomorrow is to meet China’s top brass in Beijing, where he is also expected to plead for restraint as Taiwan inaugurates president-elect William Lai (賴清德), and to raise US concerns on Chinese trade practices. However, Blinken is also seeking to stabilize ties, with tensions between the world’s two largest economies easing since his previous visit in June last year. At the
Nearly half of China’s major cities are suffering “moderate to severe” levels of subsidence, putting millions of people at risk of flooding, especially as sea levels rise, according to a study of nationwide satellite data released yesterday. The authors of the paper, published by the journal Science, found that 45 percent of China’s urban land was sinking faster than 3mm per year, with 16 percent at more than 10mm per year, driven not only by declining water tables, but also the sheer weight of the built environment. With China’s urban population already in excess of 900 million people, “even a small portion
UNSETTLING IMAGES: The scene took place in front of TV crews covering the Trump trial, with a CNN anchor calling it an ‘emotional and unbelievably disturbing moment’ A man who doused himself in an accelerant and set himself on fire outside the courthouse where former US president Donald Trump is on trial has died, police said yesterday. The New York City Police Department (NYPD) said the man was declared dead by staff at an area hospital. The man was in Collect Pond Park at about 1:30pm on Friday when he took out pamphlets espousing conspiracy theories, tossed them around, then doused himself in an accelerant and set himself on fire, officials and witnesses said. A large number of police officers were nearby when it happened. Some officers and bystanders rushed
Beijing is continuing to commit genocide and crimes against humanity against Uyghurs and other Muslim minorities in its western Xinjiang province, U.S. Secretary of State Antony Blinken said in a report published on Monday, ahead of his planned visit to China this week. The State Department’s annual human rights report, which documents abuses recorded all over the world during the previous calendar year, repeated language from previous years on the treatment of Muslims in Xinjiang, but the publication raises the issue ahead of delicate talks, including on the war in Ukraine and global trade, between the top U.S. diplomat and Chinese